The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
The BPaLM regimen, which consists four-drug combination – Bedaquiline, Pretomanid, Linezolid and Moxifloxacin, has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
The grant is designated for the research and development of Pyronaridine
Subscribe To Our Newsletter & Stay Updated
